secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-010514
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Q1 net loss $12M; ZEVASKYN approved Apr 28, PRV sold for $155M
---------------------------------------------------------------------

- Net loss of $12.0M ($0.24/share) vs. $31.6M ($1.16/share) in Q1 2024; no revenue yet.
- FDA approved ZEVASKYN on Apr 28; first QTC (Lurie Children’s) activated, first patient expected Q3 2025.
- Entered asset purchase agreement to sell rare pediatric disease PRV for gross proceeds of $155M.
- Cash and investments $84.5M at Mar 31, 2025; PRV proceeds to extend runway into early 2026.
- ~30 patients registered in Abeona Assist; value-based agreements with payers covering ~100M lives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/0001641172-25-010514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer